Lidocaine/tetracaine - Biotts
Alternative Names: MTC-A4; Tetracaine/lidocaine - BiottsLatest Information Update: 22 Nov 2022
At a glance
- Originator Biotts
- Class Acetanilides; Aminobenzoic acids; Local anaesthetics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Anaesthesia
Most Recent Events
- 21 Sep 2022 Lidocaine/tetracaine - Biotts is available for licensing as of 21 Sep 2022. https://biotts.com/en/our-products/ 3707319
- 21 Sep 2022 Preclinical trials in Anaesthesia in Poland (Transdermal), as of September 2022 (Biotts pipeline, September 2022)
- 21 Sep 2022 Biotts plans for a phase I clinical trial of lidocaine/tetracaine (Transdermal) (Biotts pipeline, September 2022)